Our data adds to the growing body of evidence indicating cell cycle pathways are profoundly affected by SNRPD3 or PRMT5 inhibition [20, 21, 38, 39, 43, 44], suggesting that combination therapy between PRMT5 and cell cycle inhibitors may be a promising avenue for further exploration in cancer therapeutics. Here, SNRPD3 is linked to cancer.